Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

With the world braced for an announcement of sweeping tariffs later today by President Donald Trump, analysts at ING have ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Prosecutors in the US are seeking the death penalty for Luigi Mangione, the man detained in connection with the assassination ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

EVERSANA – pharmaphorum's parent company – said it has met the standard to join Veeva's partner programme and will now be ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock sat down with Dr Michael Bauer, CEO of Quantro Therapeutics, ...